Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 16S ribosomal RNA (rRNA) decoding site is a highly conserved functional region within the 30S small ribosomal subunit of bacteria, essential for the accuracy of protein translation (Carter et al., 2000, Nature). It serves as the decoding center where the ribosome monitors the complementarity between the mRNA codon and the aminoacyl-tRNA anticodon to ensure high-fidelity protein synthesis (Vicens & Westhof, 2003, ChemBioChem). This site is the primary pharmacological target for aminoglycoside antibiotics, which bind specifically to the internal loop of helix 44 in the 16S rRNA (PubMed, PMC3516456). Upon binding, these drugs stabilize an active conformation of the decoding site even in the presence of incorrect tRNAs, resulting in high rates of mistranslation and the synthesis of aberrant proteins that disrupt the bacterial cell membrane (StatPearls, Aminoglycosides). While these antibiotics are potent against a broad spectrum of pathogens, their clinical use is often limited by significant side effects, such as ototoxicity and nephrotoxicity, which are frequently attributed to the structural similarity between bacterial 16S rRNA and human mitochondrial 12S rRNA (PubMed, PMC1564437). Furthermore, the emergence of resistance mechanisms, particularly the production of 16S rRNA methyltransferases that chemically modify the decoding site, remains a major challenge in treating multi-drug resistant bacterial infections (PubMed, PMC2751446).
Antibiotics bind to the 16S rRNA A-site, inducing conformational changes in residues A1492 and A1493 that mimic the state of a correct codon-anticodon match (Carter et al., 2000, Nature). This leads to the stabilization of near-cognate tRNAs, causing mRNA misreading and the production of mistranslated, toxic proteins, or physically blocks the binding of aminoacyl-tRNA to inhibit elongation (StatPearls, Aminoglycosides; PubMed, PMC3516456).
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 16S ribosomal RNA decoding site (16S rRNA A-site).